Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PLRX

PLRX - Pliant Therapeutics Inc Stock Price, Fair Value and News

13.41USD-0.77 (-5.43%)Market Closed

Market Summary

PLRX
USD13.41-0.77
Market Closed
-5.43%

PLRX Stock Price

View Fullscreen

PLRX RSI Chart

PLRX Valuation

Market Cap

855.4M

Price/Earnings (Trailing)

-5.01

Price/Sales (Trailing)

541.41

Price/Free Cashflow

-7.21

PLRX Price/Sales (Trailing)

PLRX Profitability

Return on Equity

-39.04%

Return on Assets

-32.73%

Free Cashflow Yield

-13.87%

PLRX Fundamentals

PLRX Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

PLRX Earnings

Earnings (TTM)

-170.7M

Earnings Growth (Yr)

-25.05%

Earnings Growth (Qtr)

-14.22%

Breaking Down PLRX Revenue

52 Week Range

13.3424.74
(Low)(High)

Last 7 days

-7.9%

Last 30 days

12.3%

Last 90 days

-11.5%

Trailing 12 Months

-34.0%

How does PLRX drawdown profile look like?

PLRX Financial Health

Current Ratio

16.12

Debt/Equity

0.07

Debt/Cashflow

-3.88

PLRX Investor Care

Shares Dilution (1Y)

1.98%

Diluted EPS (TTM)

-2.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20239.8M5.0M3.5M1.6M
20226.6M9.8M9.7M9.7M
202115.1M13.2M10.0M7.6M
202053.2M49.4M45.6M41.8M
201900057.1M

Tracking the Latest Insider Buys and Sells of Pliant Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 02, 2024
cummings keith lamont
acquired
43,680
2.08
21,000
chief financial officer
Jan 23, 2024
cheung lily
acquired
-
-
26,000
chief human resource officer
Jan 23, 2024
ouimette mike
acquired
-
-
31,500
general counsel & corp. sec'y
Jan 23, 2024
cummings keith lamont
acquired
-
-
55,250
chief financial officer
Jan 23, 2024
coulie bernard
acquired
-
-
128,150
president and ceo
Jan 23, 2024
hull hans
acquired
-
-
31,500
chief business officer
Jan 23, 2024
lefebvre eric
acquired
-
-
42,900
chief medical officer
Jan 17, 2024
ouimette mike
sold
-89,544
17.23
-5,197
general counsel & corp. sec'y
Jan 17, 2024
cummings keith lamont
sold
-168,527
17.23
-9,781
chief financial officer
Jan 17, 2024
coulie bernard
sold
-443,173
17.23
-25,721
president and ceo

1–10 of 50

Which funds bought or sold PLRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.14
47,557
172,557
0.02%
May 16, 2024
COMERICA BANK
unchanged
-
-292
1,356
-%
May 16, 2024
JANE STREET GROUP, LLC
added
44.61
306,392
1,920,790
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-6.54
-206,553
687,501
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
new
-
1,594,660
1,594,660
-%
May 15, 2024
Granahan Investment Management, LLC
reduced
-9.03
-5,242,380
15,598,000
0.55%
May 15, 2024
Cutter Capital Management, LP
new
-
2,892,370
2,892,370
1.11%
May 15, 2024
Deep Track Capital, LP
unchanged
-
-18,457,500
85,675,000
2.45%
May 15, 2024
Blackstone Inc.
unchanged
-
-71,282
330,869
-%
May 15, 2024
Atom Investors LP
reduced
-12.5
-336,644
865,154
0.11%

1–10 of 46

Are Funds Buying or Selling PLRX?

Are funds buying PLRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PLRX
No. of Funds

Unveiling Pliant Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
blue owl capital holdings lp
5.02%
3,004,199
SC 13G
Feb 14, 2024
price t rowe associates inc /md/
6.3%
3,788,116
SC 13G
Feb 14, 2024
deep track capital, lp
9.60%
5,750,000
SC 13G/A
Feb 14, 2024
first light asset management, llc
6.07%
3,634,510
SC 13G
Feb 14, 2024
third rock ventures iii, l.p.
0.6%
339,160
SC 13G/A
Feb 14, 2024
redmile group, llc
4.5%
2,696,648
SC 13G/A
Feb 13, 2024
vanguard group inc
5.12%
3,065,869
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
laurion capital management lp
5.98%
3,583,567
SC 13G
Jan 25, 2024
blackrock inc.
8.0%
4,801,517
SC 13G

Recent SEC filings of Pliant Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 14, 2024
8-K
Current Report
May 06, 2024
10-Q
Quarterly Report
May 06, 2024
4
Insider Trading
May 06, 2024
8-K
Current Report
Apr 22, 2024
DEF 14A
DEF 14A
Apr 22, 2024
DEFA14A
DEFA14A
Mar 12, 2024
8-K
Current Report
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
S-8
Employee Benefits Plan

Peers (Alternatives to Pliant Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Pliant Therapeutics Inc News

Latest updates
Defense World19 May 202409:51 am
MarketBeat15 May 202407:00 am
Yahoo Movies Canada13 May 202403:11 am
Defense World09 May 202411:21 am
Markets Insider01 May 202410:24 pm

Pliant Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue----2481,3321,9651,4824,9891,2491,9991,6101,7892,1744,4654,8143,60028,938-
Operating Expenses11.4%52,39247,03747,68547,57643,42739,36533,42934,63129,46026,59828,72324,69325,09323,48121,47520,57617,930-
  S&GA Expenses-100.0%-13,85415,34614,57414,15414,2518,8238,2968,5797,8467,6715,4756,5665,6274,5913,0404,011-
  R&D Expenses11.9%37,14633,18332,33933,00229,27325,11424,60626,33520,88118,75221,05219,21818,52717,85416,88417,53613,919-
Interest Expenses56.3%501321317319311317301173----------
Net Income-14.2%-46,955-41,109-41,487-41,192-37,548-35,060-30,615-29,546-28,100-24,531-27,045-22,831-22,856-19,027-16,534-17,00111,02942,169
Net Income Margin-5.8%-108.07*-102.11*-43.80*-28.73*-13.59*-12.73*-11.61*-11.09*-15.42*-12.85*-9.14*-6.14*------
Free Cashflow-26.2%-31,763-25,163-36,318-25,362-30,439-31,405-19,194-24,650-21,142-20,457-22,990-20,042------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets1.8%522512540575598351377185197221234256275296312329119
  Current Assets-3.1%490506534566588340366174185209229251271291308324112
    Cash Equivalents83.1%11663.0058.0055.0010334.0045.0025.0033.0052.0045.0035.0051.0051.0055.0017886.00
  Net PPE57.1%6.004.004.004.004.004.005.005.005.005.005.004.004.004.004.004.004.00
Liabilities118.4%84.0039.0037.0042.0036.0037.0040.0037.0023.0022.0014.0012.0011.0012.0012.0013.009.00
  Current Liabilities6.5%30.0029.0027.0030.0023.0024.0026.0023.0018.0017.0013.0011.0010.0012.0011.0012.008.00
  Long Term Debt198.4%30.0010.0010.0010.0010.0010.0010.0010.00---------
Shareholder's Equity-7.7%437474503533562313337148174199220244264283300316-
  Retained Earnings-9.4%-546-499-458-417-375-338-303-272-243-215-190-163-140-117-98.80-82.27-76.29
  Additional Paid-In Capital1.2%985973964952939654643422418414411408405401399398-
Shares Outstanding0.7%60.0060.0060.0059.0059.0049.0040.0036.0036.0036.0036.0036.00-----
Float----1,008---282---752---856-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-20.6%-30,271-25,102-36,224-24,759-30,276-31,239-18,498-24,396-20,498-19,865-22,510-19,403-13,665-16,485-15,7927,772-12,766---
  Share Based Compensation5.6%9,6669,15210,36213,04611,92310,8554,8093,4033,5312,7682,8112,2802,5781,5151,169786425---
Cashflow From Investing86.5%59,54631,92138,253-22,978-174,20820,022-178,2526,4951,53125,78332,1003,58412,23211,906-105,080-106,319-11,373---
Cashflow From Financing9848.9%21,788219699161273,326284216,29710,426-1535164491921,370237-2,365163,64051,700---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PLRX Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 0$ 1,332
Operating expenses:  
Research and development(37,146)(29,273)
General and administrative(15,246)(14,154)
Total operating expenses(52,392)(43,427)
Loss from operations(52,392)(42,095)
Interest and other income (expense), net5,8824,858
Interest expense(445)(311)
Net loss$ (46,955)$ (37,548)
Earnings Per Share [Abstract]  
Basic (USD per share)$ (0.78)$ (0.67)
Diluted (USD per share)$ (0.78)$ (0.67)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]  
Shares used in computing net loss per share - basic (in shares)60,180,92156,057,603
Shares used in computing net loss per share - diluted (in shares)60,180,92156,057,603
Comprehensive loss:  
Net loss$ (46,955)$ (37,548)
Net unrealized (loss) gain on short-term investments(834)627
Total other comprehensive (loss) gain(834)627
Comprehensive loss$ (47,789)$ (36,921)

PLRX Balance Sheet

2024-03-31
Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
[1]
Current assets  
Cash and cash equivalents$ 114,297$ 63,234
Short-term investments368,092431,011
Prepaid expenses and other current assets (Note 5)7,50911,257
Total current assets489,898505,502
Property and equipment, net5,6053,567
Operating lease right-of-use assets (Note 14)24,2281,211
Restricted cash1,4821,482
Other non-current assets392392
Total assets521,605512,154
Current liabilities  
Accounts payable7,3274,531
Accrued research and development16,42312,456
Accrued liabilities (Note 6)5,86810,219
Operating lease liabilities, current (Note 14)7731,318
Total current liabilities30,39128,524
Operating lease liabilities, non-current (Note 14)23,8800
Long-term debt (Note 7)30,00210,054
Total liabilities84,27338,578
Commitments and Contingencies (Note 13)
Stockholders’ equity  
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, and none issued or outstanding at March 31, 2024 and December 31, 2023 (Note 9)00
Common stock, $0.0001 par value per share; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; and 60,318,542 and 59,921,002 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively; (Note 10)66
Additional paid-in capital984,518972,973
Accumulated deficit(546,703)(499,748)
Accumulated other comprehensive (loss) gain(489)345
Total stockholders’ equity437,332473,576
Total liabilities and stockholders’ equity$ 521,605$ 512,154
[1]The condensed balance sheet as of December 31, 2023 has been derived from the audited financial statements as of that date.
PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
 CEO
 WEBSITEhttps://pliantrx.com
 INDUSTRYBiotechnology
 EMPLOYEES155

Pliant Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Pliant Therapeutics Inc? What does PLRX stand for in stocks?

PLRX is the stock ticker symbol of Pliant Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pliant Therapeutics Inc (PLRX)?

As of Wed May 22 2024, market cap of Pliant Therapeutics Inc is 855.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers. The fair value of Pliant Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pliant Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pliant Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLRX is over valued or under valued. Whether Pliant Therapeutics Inc is cheap or expensive depends on the assumptions which impact Pliant Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLRX.

What is Pliant Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, PLRX's PE ratio (Price to Earnings) is -5.01 and Price to Sales (PS) ratio is 541.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLRX PE ratio will change depending on the future growth rate expectations of investors.